ES2184427T3 - Uso de extractos obtenidos de iridaceas y de cimifuga racemosa y de tectorigenina como medicamento organoselectivo de tipo estrogenico sin poseer efecto uterotropico. - Google Patents

Uso de extractos obtenidos de iridaceas y de cimifuga racemosa y de tectorigenina como medicamento organoselectivo de tipo estrogenico sin poseer efecto uterotropico.

Info

Publication number
ES2184427T3
ES2184427T3 ES99913282T ES99913282T ES2184427T3 ES 2184427 T3 ES2184427 T3 ES 2184427T3 ES 99913282 T ES99913282 T ES 99913282T ES 99913282 T ES99913282 T ES 99913282T ES 2184427 T3 ES2184427 T3 ES 2184427T3
Authority
ES
Spain
Prior art keywords
organoselective
type
tectorigenine
iridaceas
cimifuga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99913282T
Other languages
English (en)
Other versions
ES2184427T5 (es
Inventor
Wolfgang Wuttke
Hubertus Jarry
Volker Christoffel
Barbara Spengler
Michael Popp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bionorica AG
Original Assignee
Bionorica AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7861630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2184427(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bionorica AG filed Critical Bionorica AG
Application granted granted Critical
Publication of ES2184427T3 publication Critical patent/ES2184427T3/es
Publication of ES2184427T5 publication Critical patent/ES2184427T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Botany (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Empleo de extractos obtenidos de iridáceas (Iridaceae) para la preparación de un medicamento organoselectivo de tipo estrógenico que carece de, o que posee, al menos, un efecto uterotrópico despreciable con la condición de que no se utilice ningún extracto obtenido de Belamcanda chinensisi, cuando el medicamento se emplee para aliviar los síntomas de la peri- y postmenopausia.
ES99913282T 1998-03-19 1999-03-19 Uso de extractos obtenidos de iridaceas y de cimifuga racemosa y de tectorigenina como medicamento organoselectivo de tipo estrogenico sin poseer efecto uterotropico. Expired - Lifetime ES2184427T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19812204A DE19812204A1 (de) 1998-03-19 1998-03-19 Verwendung von Extrakten aus Cimicifuga racemosa und Belamcanda sinensis als estrogenartiges organselektives Arzneimittel ohne uterotrope Wirkung
DE19812204 1998-03-19

Publications (2)

Publication Number Publication Date
ES2184427T3 true ES2184427T3 (es) 2003-04-01
ES2184427T5 ES2184427T5 (es) 2008-12-16

Family

ID=7861630

Family Applications (1)

Application Number Title Priority Date Filing Date
ES99913282T Expired - Lifetime ES2184427T5 (es) 1998-03-19 1999-03-19 Uso de extractos obtenidos de iridaceas y de cimifuga racemosa y de tectorigenina como medicamento organoselectivo de tipo estrogenico sin poseer efecto uterotropico.

Country Status (21)

Country Link
EP (1) EP1064009B2 (es)
JP (2) JP2002506827A (es)
KR (1) KR100623333B1 (es)
CN (2) CN100444867C (es)
AT (1) ATE225182T1 (es)
AU (1) AU755900C (es)
BR (1) BR9908256A (es)
CA (1) CA2321444C (es)
CZ (1) CZ292684B6 (es)
DE (2) DE19812204A1 (es)
DK (1) DK1064009T4 (es)
ES (1) ES2184427T5 (es)
HK (1) HK1035660A1 (es)
HU (1) HU227694B1 (es)
MX (1) MXPA00007986A (es)
PL (1) PL194096B1 (es)
PT (1) PT1064009E (es)
RU (2) RU2228188C2 (es)
SE (1) SE1064009T4 (es)
TR (1) TR200002686T2 (es)
WO (1) WO1999047149A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000302667A (ja) * 1999-04-23 2000-10-31 Kobe Tennenbutsu Kagaku Kk 豊胸促進剤
JP5106739B2 (ja) * 2000-06-29 2012-12-26 クイック−メッド テクノロジーズ、インク． 化粧品組成物および方法
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
DE10054641A1 (de) * 2000-11-03 2002-05-16 Schaper & Bruemmer Gmbh Verwendung einer Zubereitung von Cimicifuga racemosa
DE10123503A1 (de) * 2001-05-15 2002-11-21 Bionorica Ag Verwendung von Extrakten und Zubereitungen aus Irisgewächsen und Tectorigenin als organselektives Arzneimittel zur Behandlung von sexualhormon-abhängigen Erkrankungen des Urogenitaltraktes
DE10127897B4 (de) * 2001-06-08 2006-04-20 Bionorica Ag Manteltablette mit Pflanzentrockenextrakten
DE10146159A1 (de) * 2001-09-19 2003-04-10 Bionorica Ag Verwendung von Extrakten aus Cimicifuga-Arten als organselektives Arzneimittel zur Behandlung von sexualhormonabhängigen Erkrankungen des Urogenitaltraktes
EP1325681A1 (en) * 2001-12-11 2003-07-09 Société des Produits Nestlé S.A. Composition for promotion of bone growth and maintenance of bone health
DE10206390A1 (de) * 2002-02-15 2003-08-28 Bionorica Ag Verwendung von selektiv den Estrogenrezeptor beta modulierenden phytoestrogenhaltigen Extrakten
JP4605984B2 (ja) * 2002-12-20 2011-01-05 アサヒビール株式会社 ストレス緩和剤
US7902253B2 (en) * 2003-05-15 2011-03-08 Chengdu Dikang Pharmaceutical Institute Isoflavone derivatives of tectorigenin, the preparation thereof and the antiviral medicine containing the same as an effective constituent
EP1591143A1 (en) * 2004-04-26 2005-11-02 Schaper & Brümmer Gmbh & Co. Kg Composition comprising a combination of Calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
EP1588739A1 (en) * 2004-04-23 2005-10-26 Schaper & Brümmer Gmbh & Co. Kg Composition comprising a combination of calcium, Cimicifugae racemosae rhizoma and vitamin D and its use as a pharmaceutical in conditions or disorders associated with or resulting from calcium deficiency or as a nutritional supplement
US7887851B2 (en) 2004-06-07 2011-02-15 Kao Corporation Aromatase activator
CN100381435C (zh) * 2005-03-24 2008-04-16 深圳海王药业有限公司 射干总黄酮提取物及其制备方法和其在药物制备中的应用
EP1745796A1 (de) 2005-07-19 2007-01-24 Bionorica Research GmbH Kombinationspräparat insbesondere zur Therapie des Prostatakarzinoms
CN101057854B (zh) * 2006-05-31 2010-05-12 南京大学 升麻环菠萝蜜烷型三萜类化合物在抗骨质疏松及更年期综合症的用途
DE102007044916A1 (de) 2007-09-19 2009-04-23 Bionorica Ag Kosmetische oder dermatologische Zusammensetzung zur topischen Verwendung
KR100928013B1 (ko) * 2008-01-25 2009-11-24 이화여자대학교 산학협력단 범부채 추출물을 이용한 돌피의 생장 촉진방법 및 이방법을 적용한 중금속 오염 토양의 정화방법
CN101797265A (zh) * 2010-04-09 2010-08-11 中国人民解放军第二军医大学 射干总异黄酮或异黄酮类化合物在制备防治妇女病的药物或食品中的应用
EP2545932A1 (de) 2011-07-12 2013-01-16 Bionorica Se Ausgewählte Cimicifuga-Fraktionen zur Behandlung von Osteoporose
WO2013007807A1 (de) 2011-07-12 2013-01-17 Bionorica Se Ausgewählte cimicifuga-fraktionen zur behandlung von osteoporose
EP2620155A1 (de) 2012-01-30 2013-07-31 Bionorica SE Arzneimittel enthaltend Cimicifuga zur Anwendung bei der Behandlung von Sarkopenie und Herzmuskelschwäche
CN102525907B (zh) * 2012-02-22 2013-06-05 四川省中医药科学院 鸢尾苷元磺酸钠注射液
CN102631363A (zh) * 2012-04-11 2012-08-15 李超生 鸢尾苷在制备防治骨质疏松症的药物中的应用
CN104394874A (zh) * 2012-06-22 2015-03-04 国鼎生物科技股份有限公司 用于治疗动脉硬化性血管病的方法和组合物
AU2013285492B2 (en) 2012-07-03 2015-11-12 Max Zeller Soehne Ag Novel pharmacological use of Cimicifuga extract
JP2014091706A (ja) * 2012-11-02 2014-05-19 Kao Corp Ｇｌｐ−１分泌促進剤
KR101965849B1 (ko) * 2017-03-07 2019-04-04 주식회사 엘지생활건강 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물
KR101964841B1 (ko) * 2017-03-07 2019-08-07 주식회사 엘지생활건강 여성 갱년기 증상 개선용 조성물
TWI761372B (zh) * 2017-09-22 2022-04-21 日商東洋新藥股份有限公司 組合物
EP3906040A1 (en) 2018-12-31 2021-11-10 Max Zeller Söhne AG Combination of cimicifuga and petasites extracts for anticancer therapy and prophylaxis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6330417A (ja) * 1986-07-23 1988-02-09 Tsumura Juntendo Inc 抗アレルギ−剤
DE69601765T2 (de) * 1995-09-07 1999-07-08 Oreal Extrakt von Iridaceen und Zusammensetzungen, die ihn enthalten
CA2235481A1 (en) * 1995-10-23 1997-05-01 Sean M. Kerwin Compositions and methods for treating bone deficit conditions
JPH09301884A (ja) * 1996-05-15 1997-11-25 Ichimaru Pharcos Co Ltd ヒオウギ抽出物及びα−ヒドロキシ酸を含有するテストステロン５α−リダクターゼ阻害剤とその応用
JPH107580A (ja) * 1996-06-15 1998-01-13 Michio Yoshida コラゲナ−ゼ阻害剤
JP3665848B2 (ja) * 1996-09-18 2005-06-29 木村 幸代 ヒメヒオウギズイセン球根抽出液の発酵飲料及びその製造方法
DE19652183C1 (de) * 1996-12-14 1998-02-12 Schaper & Bruemmer Gmbh Verwendung eines Extraktes aus Cimicifuga racemosa

Also Published As

Publication number Publication date
CN100581541C (zh) 2010-01-20
ES2184427T5 (es) 2008-12-16
AU755900C (en) 2005-04-21
WO1999047149A1 (de) 1999-09-23
CZ20002810A3 (cs) 2000-12-13
DE19812204A1 (de) 1999-11-04
HU227694B1 (en) 2011-12-28
CZ292684B6 (cs) 2003-11-12
TR200002686T2 (tr) 2000-12-21
AU755900B2 (en) 2003-01-02
CA2321444A1 (en) 1999-09-23
KR20010040829A (ko) 2001-05-15
EP1064009A1 (de) 2001-01-03
EP1064009B1 (de) 2002-10-02
EP1064009B2 (de) 2008-07-30
SE1064009T4 (sv) 2008-09-23
ATE225182T1 (de) 2002-10-15
PL342486A1 (en) 2001-06-04
RU2003137324A (ru) 2005-06-10
EP1064009B9 (de) 2003-02-05
CA2321444C (en) 2012-10-02
SE1064009T5 (sv) 2003-04-15
DK1064009T4 (da) 2008-08-25
CN1293575A (zh) 2001-05-02
DK1064009T3 (da) 2002-11-04
HUP0200921A2 (hu) 2002-12-28
RU2263505C2 (ru) 2005-11-10
RU2228188C2 (ru) 2004-05-10
AU3146699A (en) 1999-10-11
CN1509712A (zh) 2004-07-07
HK1035660A1 (en) 2001-12-07
HUP0200921A3 (en) 2004-05-28
CN100444867C (zh) 2008-12-24
PT1064009E (pt) 2003-02-28
BR9908256A (pt) 2000-12-12
SE1064009T3 (sv) 2003-01-21
MXPA00007986A (es) 2002-08-06
KR100623333B1 (ko) 2006-12-05
JP2002506827A (ja) 2002-03-05
DE59902932D1 (de) 2002-11-07
PL194096B1 (pl) 2007-04-30
JP2010132699A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
ES2184427T3 (es) Uso de extractos obtenidos de iridaceas y de cimifuga racemosa y de tectorigenina como medicamento organoselectivo de tipo estrogenico sin poseer efecto uterotropico.
Boozari et al. Natural products for COVID‐19 prevention and treatment regarding to previous coronavirus infections and novel studies
Sumbul et al. Role of phenolic compounds in peptic ulcer: An overview
Fukai et al. Antimicrobial activity of licorice flavonoids against methicillin-resistant Staphylococcus aureus
Hudaib et al. Xanthine oxidase inhibitory activity of the methanolic extracts of selected Jordanian medicinal plants
Lim et al. Recent insights on anti-dengue virus (DENV) medicinal plants: review on in vitro, in vivo and in silico discoveries
ATE304368T1 (de) Kräuterpflanzen enthaltende artzneimittel
Lee et al. Effects of Humulus lupulus extract on the central nervous system in mice
Lee et al. Prenylisoflavonoids from Erythrina senegalensis as novel HIV-1 protease inhibitors
MX9202152A (es) Derivados del indol, procedimiento para su preparacion y composicion farmaceutica que los contiene.
de Sousa et al. New cytotoxic bibenzyl and other constituents from Bauhinia ungulata L.(Fabaceae)
AR008908A1 (es) Uso de loratadina y un descongestivo para preparar un medicamento para mejorar la funcion pulmonar de un paciente que padece asma
ZHANG Research progress on chemical constituents and pharmacological effects of Prunella vulgaris
Salinas-Sánchez et al. Effect of hautriwaic acid isolated from Dodonaea viscosa in a model of kaolin/carrageenan-induced monoarthritis
Kakorin et al. Potential biological activity and chemical composition of Caragana Jubata (pall.) Poir.
Youn et al. Apoptosis‐inducing and Antitumor Activity of Neolignans Isolated from Magnolia officinalis in HeLa Cancer Cells
Beedimani et al. Hepatoprotective activity of Eclipta alba against carbon tetrachloride-induced hepatotoxicity in albino rats
Mitra et al. Promising plant-based bioactive natural products in combating SARS-CoV2 Novel Corona (COVID-19) virus infection
Win et al. Dinorcassane diterpenoid from Boesenbergia rotunda rhizomes collected in lower Myanmar
Igbe et al. Analgesic and anti-inflammatory activity of the aqueous leaf extract of Piliostigma thonningii (Caesalpinoideae)
ES2125846T3 (es) Nuevas indicaciones para el empleo de inductores de parainmunidad multipotentes a partir de virus de viruela o virus de paraviruela atenuados, no inmunogenos, como medicamento.
Xue et al. Non-hypoglycemic effect of metformin in renal protection: a literature review
Zainulddin et al. Anti-ulcer activity of the aqueous extract of Melastoma malabathricum L. leaf in rats
Hemalika et al. Potential traditional medicinal plants for COVID-19 management in Sri Lanka: A review
Su et al. New cytotoxic alkylated chalcones from fatoua villosa